FDA approves point-of-care PSA test
medwireNews: The US FDA has granted marketing approval for a point-of-care device for the measurement of prostate-specific antigen (PSA).
The Sangia Total PSA Test (OPKO Diagnostics, LLC, Woburn, Massachusetts, USA) uses a finger prick test to collect a blood sample and can generate a PSA result within 15 minutes. The test is approved for use in patients aged 50 years or older following results from a clinical trial of 434 men attending 10 different US centers.
The test may be used alongside a prostate biopsy for the diagnosis of prostate cancer.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group